Literature DB >> 18752307

Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization.

Daniela del Gaudio1, Yaping Yang, Barbara A Boggs, Eric S Schmitt, Jennifer A Lee, Trilochan Sahoo, Hoang T Pham, Joanna Wiszniewska, A Craig Chinault, Arthur L Beaudet, Christine M Eng.   

Abstract

The dystrophinopathies, which include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy, are X-linked recessive neuromuscular disorders caused by mutations in the dystrophin gene (DMD). Approximately 70% of mutations causing DMD/BMD are deletions or duplications and the remainder are point mutations. Current clinical diagnostic strategies have limits of resolution that make detection of small DMD deletions and duplications difficult to identify. We developed an oligonucleotide-based array comparative genomic hybridization (array-CGH) platform for the enhanced identification of deletions and duplications in the DMD gene. Using this platform, 39 previously characterized patient samples were analyzed, resulting in the accurate identification of 38 out of 39 rearrangements. Array-CGH did not identify a 191-bp deletion partially involving exon 19 that created a junction fragment detectable by Southern hybridization. To further evaluate the sensitivity and specificity of this array, we performed concurrent blinded analyses by conventional methodologies and array-CGH of 302 samples submitted to our clinical laboratory for DMD deletion/duplication testing. Results obtained on the array-CGH platform were concordant with conventional methodologies in 300 cases, including 69 with clinically-significant rearrangements. In addition, the oligonucleotide array-CGH platform detected two duplications that conventional methods failed to identify. Five copy-number variations (CNVs) were identified; small size and location within introns predict the benign nature of these CNVs with negligible effect on gene function. These results demonstrate the utility of this array-CGH platform in detecting submicroscopic copy-number changes involving the DMD gene, as well as providing more precise breakpoint identification at high-resolution and with improved sensitivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752307     DOI: 10.1002/humu.20841

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  32 in total

1.  Detection of clinically relevant exonic copy-number changes by array CGH.

Authors:  Philip M Boone; Carlos A Bacino; Chad A Shaw; Patricia A Eng; Patricia M Hixson; Amber N Pursley; Sung-Hae L Kang; Yaping Yang; Joanna Wiszniewska; Beata A Nowakowska; Daniela del Gaudio; Zhilian Xia; Gayle Simpson-Patel; LaDonna L Immken; James B Gibson; Anne C-H Tsai; Jennifer A Bowers; Tyler E Reimschisel; Christian P Schaaf; Lorraine Potocki; Fernando Scaglia; Tomasz Gambin; Maciej Sykulski; Magdalena Bartnik; Katarzyna Derwinska; Barbara Wisniowiecka-Kowalnik; Seema R Lalani; Frank J Probst; Weimin Bi; Arthur L Beaudet; Ankita Patel; James R Lupski; Sau Wai Cheung; Pawel Stankiewicz
Journal:  Hum Mutat       Date:  2010-11-02       Impact factor: 4.878

2.  Becker muscular dystrophy due to an inversion of exons 23 and 24 of the DMD gene.

Authors:  Kevin M Flanigan; Diane Dunn; C Aaron Larsen; Livija Medne; Carsten B Bönnemann; Robert B Weiss
Journal:  Muscle Nerve       Date:  2011-11       Impact factor: 3.217

3.  One hundred twenty-one dystrophin point mutations detected from stored DNA samples by combinatorial denaturing high-performance liquid chromatography.

Authors:  Annalaura Torella; Amelia Trimarco; Francesca Del Vecchio Blanco; Anna Cuomo; Stefania Aurino; Giulio Piluso; Carlo Minetti; Luisa Politano; Vincenzo Nigro
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

4.  Clinical Utility Gene Card for: Becker muscular dystrophy.

Authors:  David Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-02-21       Impact factor: 4.246

5.  Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies.

Authors:  Nigel G Laing; Mark R Davis; Klair Bayley; Sue Fletcher; Steve D Wilton
Journal:  Clin Biochem Rev       Date:  2011-08

6.  De novo mutation in DMD gene in a patient with combined hemophilia A and Duchenne muscular dystrophy.

Authors:  Lana Strmecki; Petra Hudler; Majda Benedik-Dolničar; Radovan Komel
Journal:  Int J Hematol       Date:  2013-12-08       Impact factor: 2.490

7.  Evolution of molecular diagnosis of Duchenne muscular dystrophy.

Authors:  Afaf Ben Itto; Khalil Hamzi; Hanane Bellayou; Mohammed Itri; Ilham Slassi; Sellama Nadifi
Journal:  J Mol Neurosci       Date:  2013-02-05       Impact factor: 3.444

8.  Regional genomic instability predisposes to complex dystrophin gene rearrangements.

Authors:  Junko Oshima; Daniel B Magner; Jennifer A Lee; Amy M Breman; Eric S Schmitt; Lisa D White; Carol A Crowe; Michelle Merrill; Parul Jayakar; Aparna Rajadhyaksha; Christine M Eng; Daniela del Gaudio
Journal:  Hum Genet       Date:  2009-05-16       Impact factor: 4.132

9.  Apparent homozygosity of a novel frame shift mutation in the CFTR gene because of a large deletion.

Authors:  Feras M Hantash; Arlene Rebuyon; Mei Peng; Joy B Redman; Weimin Sun; Charles M Strom
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

10.  CUGC for Duchenne muscular dystrophy (DMD).

Authors:  David J Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-01-12       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.